Oric Pharmaceuticals Inc. Common Stock (ORIC)

FairStock Score: 48/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the numbers. Oric has no revenue in the filed figures, and it has not earned a profit in the last four years. In fiscal 2023 it lost $100.7 million; in fiscal 2024, $127.8 million; in fiscal 2025, $129.5 million. In the June 2026 quarter alone, net loss was $41.5 million, or $0.38 per diluted share. Trailing free cash flow is negative $112.3 million, a negative 9.6% FCF yield. At the close on 2026-10-13, FairStock calculations show P/E -8.70, P/B 3.07, ROE -39.8%, ROCE -25.97%, and Piotroski 0/9. Those are not the markings of a mature business with a moat; they are the markings of a clinical-stage bet. The balance sheet shows little debt, with D/E 0.02, and Altman Z 28.11, so near-term solvency risk may not be immediate. But low debt does not create value if the company must keep spending. The business is a Phase 1b oncology program, enozertinib/ORIC-114, targeting EGFR exon 20 and HER2 exon 20. If it works, the value could be substantial; if it fails, there is little earnings support beneath the $1.2 billion market cap. At $11.31, the market is pricing hope, not current cash flows. Graham would call this speculation unless the pipeline is bought at a discount to probable worth. FairStock score 48/100 and no Lynch category because of persistent losses reinforce caution. I would need clinical proof, cash runway, and dilution risk before calling it a value opportunity.

In plain English: Oric Pharmaceuticals is a small clinical-stage cancer drug developer with 111 employees. It has no reported revenue and has lost money each of the last four years, including a $41.5 million loss in the quarter ended June 30, 2026. At the close on 2026-10-13, its $1.2 billion market value rests mostly on whether its experimental drug works, so the price looks speculative rather than clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer